Table 1. Clinical and pathological features according to surgery modalities.
| |
ALND |
SLNB |
SLNB+ALNDa |
|
|||
|---|---|---|---|---|---|---|---|
| Variables | N | % | N | % | N | % | P-value |
|
Hospital |
|
|
|
|
|
|
<0.0001 |
| CGFL |
143 |
86.7 |
103 |
59.5 |
37 |
86.0 |
|
| Private hospital of Dijon |
17 |
10.3 |
24 |
13.9 |
5 |
11.6 |
|
| Le Creusot |
0 |
0.0 |
17 |
9.8 |
0 |
0.0 |
|
| Chalon sur Saône |
4 |
2.4 |
14 |
8.1 |
1 |
2.3 |
|
| Macon |
1 |
0.6 |
15 |
8.7 |
0 |
0.0 |
|
|
Hormone status |
|
|
|
|
|
|
0.04 |
| Premenopausal |
43 |
26.1 |
26 |
15.0 |
9 |
20.9 |
|
| Postmenopausal |
122 |
73.9 |
146 |
84.4 |
34 |
79.1 |
|
| Unknown |
0 |
0.0 |
1 |
0.6 |
0 |
0.0 |
|
|
HRT |
|
|
|
|
|
|
0.08 |
| Yes |
34 |
20.6 |
45 |
26.0 |
6 |
14.0 |
|
| No |
106 |
64.2 |
96 |
55.5 |
33 |
76.7 |
|
| Unknown |
25 |
15.2 |
32 |
18.5 |
4 |
9.3 |
|
|
Tumour histology |
|
|
|
|
|
|
0.001 |
| Invasive ductal |
134 |
81.2 |
133 |
76.9 |
37 |
86.0 |
|
| Invasive lobular |
17 |
10.3 |
9 |
5.2 |
3 |
7.0 |
|
|
In situ |
6 |
3.6 |
23 |
13.3 |
0 |
0.0 |
|
| Medullary cancer |
1 |
0.6 |
0 |
0 |
1 |
2.3 |
|
| micro-invasive cancer |
1 |
0.6 |
1 |
0.6 |
1 |
2.3 |
|
| Unknown |
6 |
3.6 |
7 |
4.0 |
1 |
2.3 |
|
|
SBR Grade |
|
|
|
|
|
|
<0.0001 |
| 1 |
32 |
19.4 |
69 |
39.9 |
10 |
23.3 |
|
| 2 |
64 |
38.8 |
56 |
32.4 |
21 |
48.8 |
|
| 3 |
52 |
31.5 |
19 |
11.0 |
10 |
23.3 |
|
| Unknown |
17 |
10.3 |
29 |
16.8 |
2 |
4.7 |
|
|
C-erb-2 status |
|
0.0 |
|
0.0 |
|
0.0 |
0.34 |
| Positive |
25 |
15.2 |
14 |
8.1 |
4 |
9.3 |
|
| Negative |
121 |
73.3 |
104 |
60.1 |
36 |
83.7 |
|
| Unknown |
19 |
11.5 |
55 |
31.8 |
3 |
7.0 |
|
|
Hormone receptor status |
|
|
|
|
|
|
0.95 |
| Positive |
120 |
72.7 |
113 |
65.3 |
33 |
76.7 |
|
| Negative |
25 |
15.2 |
22 |
12.7 |
6 |
14.0 |
|
| Unknown |
20 |
12.1 |
38 |
22.0 |
4 |
9.3 |
|
|
Treatments |
|
0.0 |
|
0.0 |
|
0.0 |
|
|
Surgery |
|
|
|
|
|
|
<0.0001 |
| Lumpectomy |
88 |
53.3 |
155 |
89.6 |
42 |
97.7 |
|
| Mastectomy |
77 |
46.7 |
17 |
9.8 |
1 |
2.3 |
|
| Unknown |
0 |
0.0 |
1 |
0.6 |
0 |
0.0 |
|
|
Adjuvant chemotherapy |
|
|
|
|
|
|
<0.0001 |
| Yes |
111 |
67.3 |
28 |
16.2 |
28 |
65.1 |
|
| No |
54 |
32.7 |
141 |
81.5 |
15 |
34.9 |
|
| Unknown |
0 |
0.0 |
4 |
2.3 |
0 |
0.0 |
|
|
Radiotherapy |
|
|
|
|
|
|
0.16 |
| Yes |
139 |
84.2 |
149 |
86.1 |
41 |
95.3 |
|
| No |
26 |
15.8 |
23 |
13.3 |
2 |
4.7 |
|
| Unknown |
0 |
0.0 |
1 |
0.6 |
0 |
0.0 |
|
|
Hormone therapy |
|
|
|
|
|
|
<0.0001 |
| Yes |
135 |
81.8 |
108 |
62.4 |
34 |
79.1 |
|
| No |
29 |
17.6 |
65 |
37.6 |
8 |
18.6 |
|
| Unknown |
1 |
0.6 |
0 |
0.0 |
1 |
2.3 |
|
|
Breast reconstruction |
|
|
|
|
|
|
0.07 |
| Yes |
22 |
13.3 |
12 |
6.9 |
2 |
4.7 |
|
| No |
140 |
84.8 |
158 |
91.3 |
40 |
93.0 |
|
| Unknown |
3 |
1.8 |
3 |
1.7 |
1 |
2.3 |
|
|
Lymphedema |
|
|
|
|
|
|
<0.0001 |
| Yes |
17 |
10.3 |
0 |
0.0 |
3 |
7.0 |
|
| No |
143 |
86.7 |
170 |
98.3 |
39 |
90.7 |
|
| Unknown |
5 |
3.0 |
3 |
1.7 |
1 |
2.3 |
|
|
Type of monitoring |
|
|
|
|
|
|
0.91 |
| Regular |
154 |
93.3 |
160 |
92.5 |
41 |
95.3 |
|
| Irregular |
8 |
4.8 |
10 |
5.8 |
2 |
4.7 |
|
| Unknown |
3 |
1.8 |
3 |
1.7 |
0 |
0.0 |
|
|
Recurrence |
|
|
|
|
|
|
0.62 |
| Yes |
10 |
6.1 |
9 |
5.2 |
4 |
9.3 |
|
| No |
150 |
90.9 |
161 |
93.1 |
39 |
90.7 |
|
| Unknown |
5 |
3.0 |
3 |
1.7 |
0 |
0.0 |
|
|
Tumour size (mm) |
|
|
|
|
|
|
0.0001 |
| ⩽10 mm |
35 |
21.2 |
91 |
52.6 |
10 |
23.3 |
|
| 10–20 mm |
54 |
32.7 |
71 |
41.0 |
28 |
65.1 |
|
| >10 mm |
72 |
43.6 |
5 |
2.9 |
5 |
11.6 |
|
| Unknown | 4 | 2.4 | 6 | 3.5 | 0 | 0.0 | |
Abbreviations: ALND=axillary lymph node dissection; CGFL=Centre Georges François Leclerc; HRT=hormone replacement therapy; SBR=Scarff Bloom and Richardson; SLNB=sentinel lymph node biopsy.
Kruskal–Wallis test was used to test the homogeneity of the different groups for quantitative variables; Pearson's χ2-test was used to test the homogeneity of the different groups for qualitative variables.
a
Forty patients had SLNB+ALND at the same time.